This newslink doesn't exist or it was removed.
Go to Homempage.
The New York Times USA Business July 22, 2023
In 2004, Gilead Sciences decided to stop pursuing a new H.I.V. drug. The was that it wasn’t sufficiently different from an existing treatment to warrant further development.In private, though, something else was at play. Gilead had to delay the new drug’s release to maximize... + más
Opinion | The New York Times
Alzheimer's Q&A: Bright light therapy has multiple benefits | The Advocate
Forbes USA Business September 24, 2022
Following another ugly market week, the average U.S. stock is now trading in Bear Market territory. Of course, such was also the case in 2020 and 2018 and 2016 and more than a few other periods throughout market history. Such is the hardship that must be endured to achieve... + más
What is storm surge, and what contributes to the deadly hurricane hazard? | CBS News
Early-adopter tax is in full force for the first batch of AM5 motherboards | Ars Technica
Slate USA Tech October 01, 2022
. This article contains spoilers about the first few episodes of Season 5 of The Handmaid’s Tale. Four episodes into the fifth season of The Handmaid’s Tale, not much has changed. We still don’t really . Approximately 15 percent of the show’s runtime remains devoted to... + más
Handmaid's Tale, Girls Who Code and other books just banned in the U.S. | Newsweek
Call of Duty: Modern Warfare 2 Xbox beta start time | Newsweek
Forbes USA Business October 21, 2022
Elisabeth Moss and Yvonne Strahovski in Season 5 of 'The Handmaid's Tale' on Hulu. PHOTO COURTESY OF HULU. Why would former Handmaid June Osborne help Serena Waterford, the woman who brutalized her for years, deliver her baby? June had many choices in that... + más
Serena Williams Plans Her Post-Tennis ‘Second Career’ With Venture Capitalist Firm | The Root
Kennywood memories turn into chaos and fear for Phantom Fall Fest attendees after shooting | PennLive
MarketWatch USA Business December 21, 2023
The Gilead story starts with the company’s dominant HIV business. Analysts are looking for low-single-digit sales growth annually to just over $28 billion by 2025. While some drugs see patent expirations, loss of market share, and declining sales, Biktarvy, its HIV treatment ,... + más
How a Drug Maker Profited by Slow-Walking a Promising H.I.V. Therapy | The New York Times
2022 Associated Press All-America Team | Associated Press
About iurex | Privacy Policy | Disclaimer |